Serum Metabonomics Reveals Risk Factors in Different Periods of Cerebral Infarction in Humans

Guoyou Chen; Li Guo; Xinjie Zhao; Yachao Ren; Hongyang Chen; Jincheng Liu; Jiaqi Jiang; Peijia Liu; Xiaoying Liu; Bo Hu; Na Wang; Haisheng Peng; Guowang Xu; Haiquan Tao

doi:10.3389/fmolb.2021.784288

Serum Metabonomics Reveals Risk Factors in Different Periods of Cerebral Infarction in Humans

Front Mol Biosci. 2022 Feb 15:8:784288. doi: 10.3389/fmolb.2021.784288. eCollection 2021.

Authors

Guoyou Chen¹, Li Guo², Xinjie Zhao³, Yachao Ren¹, Hongyang Chen¹, Jincheng Liu⁴, Jiaqi Jiang¹, Peijia Liu⁵, Xiaoying Liu¹, Bo Hu¹, Na Wang¹, Haisheng Peng¹, Guowang Xu³, Haiquan Tao^{6

7}

Affiliations

¹ College of Pharmacy, Harbin Medical University-Daqing, Daqing, China.
² Department of Anesthesia, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, China.
³ Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
⁴ Academic Affairs Office, Harbin Medical University-Daqing, Daqing, China.
⁵ Department of Clinical Laboratory, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
⁶ Department of Neurosurgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
⁷ Cerebrovascular Diseases Department, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, China.

Abstract

Studies of key metabolite variations and their biological mechanisms in cerebral infarction (CI) have increased our understanding of the pathophysiology of the disease. However, how metabolite variations in different periods of CI influence these biological processes and whether key metabolites from different periods may better predict disease progression are still unknown. We performed a systematic investigation using the metabonomics method. Various metabolites in different pathways were investigated by serum metabolic profiling of 143 patients diagnosed with CI and 59 healthy controls. Phe-Phe, carnitine C18:1, palmitic acid, cis-8,11,14-eicosatrienoic acid, palmitoleic acid, 1-linoleoyl-rac-glycerol, MAG 18:1, MAG 20:3, phosphoric acid, 5α-dihydrotestosterone, Ca, K, and GGT were the major components in the early period of CI. GCDCA, glycocholate, PC 36:5, LPC 18:2, and PA showed obvious changes in the intermediate time. In contrast, trans-vaccenic acid, linolenic acid, linoleic acid, all-cis-4,7,10,13,16-docosapentaenoic acid, arachidonic acid, DHA, FFA 18:1, FFA 18:2, FFA 18:3, FFA 20:4, FFA 22:6, PC 34:1, PC 36:3, PC 38:4, ALP, and Crea displayed changes in the later time. More importantly, we found that phenylalanine metabolism, medium-chain acylcarnitines, long-chain acylcarnitines, choline, DHEA, LPC 18:0, LPC 18:1, FFA 18:0, FFA 22:4, TG, ALB, IDBIL, and DBIL played vital roles in the development of different periods of CI. Increased phenylacetyl-L-glutamine was detected and may be a biomarker for CI. It was of great significance that we identified key metabolic pathways and risk metabolites in different periods of CI different from those previously reported. Specific data are detailed in the Conclusion section. In addition, we also explored metabolite differences of CI patients complicated with high blood glucose compared with healthy controls. Further work in this area may inform personalized treatment approaches in clinical practice for CI by experimentally elucidating the pathophysiological mechanisms.

Keywords: cerebral infarction; different periods; human serum; key metabolites and pathways; metabonomics.